GET DAILY SIGNALSCardio Diagnostics Holdings (CDIO): Examining Its Epigenetic Approach to Cardiovascular Testing
Key Takeaways
- CDIO is the Nasdaq ticker for Cardio Diagnostics Holdings, Inc., a Chicago-based molecular diagnostics company focused on cardiovascular disease.
- The company develops epigenetics- and genetics-based blood tests, led by Epi+Gen CHD and PrecisionCHD, aimed at assessing and detecting coronary heart disease.
- Cardio Diagnostics became publicly traded in 2022 through a business combination and remains an early-stage, emerging growth company with a small workforce and limited revenue.
- Its core technology is built on DNA methylation biomarkers licensed from the University of Iowa Research Foundation.
- As a clinical-stage diagnostics firm, CDIO carries elevated risks tied to commercialization, reimbursement, and ongoing capital needs.
Company Background
Cardio Diagnostics Holdings, Inc. (CDIO) develops and commercializes precision molecular tests for cardiovascular disease. The goal is to help clinicians detect issues earlier and assess risk more precisely through a routine blood draw. I find this positioning noteworthy because it sits at the intersection of rising cardiovascular disease prevalence and the move toward more personalized, data-driven medicine.
Profile and Business Model
The company was founded in 2017 and is headquartered in Chicago, Illinois. It became publicly traded on the Nasdaq in October 2022 through a business combination with Mana Capital Acquisition Corp., a SPAC, under which the legacy operating business became a wholly owned subsidiary. As a smaller reporting company, it operates with a relatively small team and remains in an early phase of commercialization.
Its business model centers on proprietary, blood-based tests that combine epigenetic and genetic analysis. Epigenetics refers to chemical changes, such as DNA methylation, that affect how genes are expressed without altering the underlying DNA sequence. When screening for comparable names in the space, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Flagship products include Epi+Gen CHD, a blood test for three-year risk assessment of symptomatic coronary heart disease events; PrecisionCHD, an integrated epigenetic-genetic test to aid detection of coronary heart disease; Actionable Clinical Intelligence, a platform delivering epigenetic and genetic insights for chronic care management; HeartRisk, a SaaS cardiovascular disease risk intelligence platform; and CardioInnovate360, a research-use-only solution for biopharmaceutical discovery and validation.
The underlying technology is licensed from the University of Iowa Research Foundation. Tests are marketed to telemedicine providers, concierge and longevity clinics, risk-bearing provider organizations, and employer groups. Emphasis on accessibility through a standard blood sample sets it apart from traditional cholesterol and imaging-based approaches. Financially, the company is pre-profit with minimal revenue and continues to fund operations through equity financing while investing in test validation, laboratory infrastructure, and commercialization.
Why Investors Follow CDIO
Interest stems largely from thematic drivers. Cardiovascular disease remains a leading global cause of death, creating a sizable potential market for earlier and more accurate detection. The epigenetic approach offers differentiation from conventional risk calculators and lipid panels, potentially delivering a more personalized risk profile. The company has built in-house laboratory capacity, including a CLIA-certified facility in Iowa City, Iowa, providing end-to-end control over test processing. Beyond core tests, data and software assets like the HeartRisk platform point toward a broader cardiovascular precision medicine ecosystem. Coverage announcements from provider networks remain important signals, given the role of reimbursement in long-term prospects.
Risks and Key Considerations
Investing in CDIO involves substantial risks typical of early-stage diagnostics companies. Limited revenue and ongoing operating losses mean additional capital may be needed. Success hinges on regulatory clearances, securing reimbursement, and scaling provider adoption. The competitive landscape includes established diagnostics firms and emerging precision medicine players. Technology and regulatory risks exist around demonstrating clinical utility, while changes in reimbursement policy or laboratory regulations could affect demand. As a small-cap stock with limited float and a history of equity raises, CDIO may face significant price volatility and dilution risk.
Conclusion
Cardio Diagnostics Holdings offers a science-driven approach to cardiovascular care through epigenetic and genetic blood testing within the expanding field of precision diagnostics. Its profile reflects both ambition and the realities of an early-stage firm working toward commercial scale and profitability. For investors, CDIO represents a high-risk, high-uncertainty exposure to an emerging healthcare niche whose long-term relevance will depend on clinical adoption, reimbursement, and execution.
Using Tickeron Tools for Research
One tool I rely on regularly is Tickeron’s AI Screener. It helps filter stocks and ETFs using technical indicators, fundamentals, AI signals, and custom criteria, which has proven practical when evaluating emerging healthcare companies and comparing them across industries.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
CDIO's RSI Indicator ascending out of oversold territory
The RSI Indicator for CDIO moved out of oversold territory on October 15, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 50 similar instances when the indicator left oversold territory. In 46 of the 50 cases the stock moved higher. This puts the odds of a move higher at 90%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 38 of 54 cases where CDIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for CDIO just turned positive on November 06, 2026. Looking at past instances where CDIO's MACD turned positive, the stock continued to rise in 20 of 38 cases over the following month. The odds of a continued upward trend are 53%.
Following a +5.00% 3-day Advance, the price is estimated to grow further. Considering data from situations where CDIO advanced for three days, in 113 of 154 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
CDIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 58 of 136 cases where CDIO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 43%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CDIO as a result. In 47 of 64 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
CDIO moved below its 50-day moving average on October 08, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CDIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 9 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CDIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 47 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 70 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.654) is normal, around the industry mean (3.498). P/E Ratio (-0.566) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (322.581) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 74 (best 1 - 100 worst), indicating slightly worse than average price growth. CDIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CDIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement